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Edited by Veli-Pekka LehtoAbstract Apoptosis repressor with caspase recruitment domain
is expressed at high levels in brain and myogenic tissues, consis-
tent with a role to inhibit apoptosis in the terminally diﬀerenti-
ated cells. Expression of ARC in cancers is not known. In this
study, we reported that ARC was highly expressed in various
non-myogenic and non-neurogenic human and rat cancer cell
lines. Unexpectedly, ARC was localized almost exclusively to
the nuclei of cancer cells, which was unlike the cytoplasmic local-
ization of ARC in non-cancer cells. Furthermore, nuclear ARC
in cancer cells did not co-localize with nucleolus protein of
30 kDa, an alternatively spliced ARC isoform. These ﬁndings
indicate that ARC is distributed diﬀerently in cancer cells than
non-cancer cells and thus might play a role in neoplastic trans-
formation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis plays a critical role in adult tissue homeostasis.
The failure of cells to undergo apoptotic cell death is a factor
in the pathogenesis of various human diseases, including can-
cers, autoimmune diseases, and viral infections [1]. The human
apoptosis repressor with caspase recruitment domain (ARC)
gene was ﬁrst identiﬁed by screening for proteins with homol-
ogy to the caspase recruitment domain (CARD) of caspase-9
[2]. ARC is highly expressed in brain and myogenic tissues,
e.g., skeletal muscle and heart [2,3]. Endogenous ARC is pre-
dominantly cytoplasmic in rat embryonic heart H9c2 cells
and mouse skeletal muscle tissue [3,4]. ARC protects cells
against apoptosis triggered by several stimuli, including hydro-
gen peroxide, hypoxia, and Fas ligand [3,5,6]. Protein–protein
interactions of ARC with Fas, Fas-associated death domainAbbreviations: ARC, apoptosis repressor with CARD domain; CARD,
caspase recruitment domain; CK2, casein kinase II; Nop30, nucleolus
protein of 30 kDa; NQO-1, NAD(P)H:quinone oxidoreductase 1;
NLS, nuclear localization signal; YY-1, YinYang 1
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doi:10.1016/j.febslet.2005.03.040and Bax regulate inhibition of apoptosis in a CARD depen-
dent manner [2,6,7]. Therefore, ARC inhibits both extrinsic
and intrinsic cell death pathways. Basal levels of ARC in
cardiomyocytes, neurons, and skeletal muscle ﬁbers serve to
repress apoptosis in these terminally diﬀerentiated cells.
Knockdown of endogenous ARC facilitates death-inducing
signaling complex assembly and triggers spontaneous Bax acti-
vation and apoptosis [6]. Expression of ARC in cancer cells
has not been reported. Here, we show that ARC is expressed
in various human and rat cancer cells. However, in contrast
to the non-cancer cells, ARC is localized almost exclusively
to nuclei.2. Materials and methods
2.1. Cell culture
Human MIA PaCa-2 pancreatic carcinoma, U-87 glioblastoma,
HeLa cervical carcinoma, MDA-MB-231 mammary gland adenocarci-
noma, DU 145 prostate carcinoma, BJAB and DG-75 lymphoma cells;
non-transformed H9c2 embryonic rat heart derived cells, rat N1-S1,
McA-RH7777, and ASD30 hepatoma, and PC6 pheochromocytoma
cells were grown in Dulbeccos modiﬁed Eagles medium (DMEM).
HCT 116 wild type human colorectal carcinoma cells as well as
HCT 116 Bax+/ and HCT Bax/ cells were maintained in McCoys
5a medium. SH-SY5Y human neuroblastoma cells were maintained
in DMEM/F-12 medium. All media were purchased from Gibco and
supplemented with 10% fetal bovine serum, 50 units/ml of penicillin
and 50 lg/ml of streptomycin. Primary cultured rat hippocampal neu-
rons were maintained in Neurobasal-A containing 2% B27 supplement,
2 mM Glutamax-1. Cells were incubated in a humidiﬁed 37 C incuba-
tor containing 5% CO2 and 95% air.2.2. Western blot analysis
Cell and tissue extracts were prepared in ice-cold RIPA lysis buﬀer
(150 mM NaCl, 1 mM EGTA, 1% sodium deoxycholate, 1% Triton
X-100, and 50 mM Tris–Cl, pH 8.0) supplemented with a cocktail
of protease inhibitors (Roche Diagnostics). Fresh human skeletal
muscle was obtained from the Human Tissue Procurement Depart-
ment, University Hospitals of Cleveland. Protein samples (50 lg)
were diluted in sample buﬀer (200 mM Tris–Cl, 15% glycerol, 10%
SDS, 5% b-mercaptoethanol, and 0.01% phenol blue, pH 6.8) and re-
solved on 12% SDS–PAGE gel. Proteins were then transferred and
immobilized onto PVDF membranes and probed with a polyclonal
anti-ARC antibody and anti-rabbit secondary antibody. ARC anti-
body was raised against a GST-ARC fusion protein and was aﬃnity
puriﬁed using the C-terminal proline–glutamic acid (P/E)-rich domain
[8]. b-Tubulin was detected with a monoclonal anti-b-tubulin anti-
body (Sigma, 1:1000) and anti-mouse secondary antibody. YY1
and NQO1 were detected with monoclonal anti-YY1 antibody (Santa
Cruz, 1:1000) and anti-NQO1 antibody (Santa Cruz, 1:2000),
respectively.blished by Elsevier B.V. All rights reserved.
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The nuclear and cytoplasmic extracts were prepared as previously
described with minor modiﬁcations [9]. Brieﬂy, cells cultured on 150-
mm Petri dishes were scraped into 1 ml of ice-cold PBS. Cells were cen-
trifuged at 4000 · g for 5 min at 4 C, and cell pellets were lysed in
300 ll of buﬀer (20 mM HEPES, 20% glycerol, 10 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, and 0.1% Triton X-100, pH 7.6) on
ice. After 20 min incubation, supernatants were collected as cytoplas-
mic extracts after centrifugation (4000 · g for 5 min at 4 C). Pellets
were lysed in 30 ll of buﬀer (20 mM HEPES, 20% glycerol, 500 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 0.1% Triton X-100, pH
7.6). After 20 min incubation on ice, supernatants were collected as nu-
clear extracts after centrifugation (16000 · g for 15 min at 4 C).
2.4. Immunocytochemistry
HCT 116, MDA-MB 231, and MIA PaCa-2 cells cultured on glass
coverslips were ﬁxed with 1% paraformaldehyde overnight at 4 C
and permeabilized in 0.05% Triton X-100 for 5 min at room tempera-
ture. After washes, cells were blocked with 1% BSA for 2 h, followed
by incubation with primary antibody against ARC overnight at
4 C. Cells were then washed with PBS followed by incubation with
Alexa Fluor 488 or 543 anti-rabbit IgG for 1 h at room temperature.
Hoechst 33342 (1 lg/ml) was included to stain nuclei.
Samples of human skeletal muscles were cut into 1 cm3 blocks and
ﬁxed overnight with 1% paraformaldehyde at 4 C. Blocks were placed
successively into 10%, 20% and 30% sucrose, respectively for 8 h at
4 C and frozen in embedding medium cooled on dry ice (Tissue-
Tek). Frozen tissue sections were permeabilized with 0.05% Triton
X-100 for 5 min and blocked with 10% goat serum and 1% BSA in
PBS for 2 h at room temperature. After incubation in primary anti-
body against ARC for 2 h at room temperature, sections were washed
with PBS, followed by incubation with anti-rabbit Alexa Fluor 488 or
543 for 1 h. Images of Alexa Fluor 488 ﬂuorescence was collected using
488-nm excitation and >505-nm emission ﬁlters. Alexa Fluor 543 ﬂuo-
rescence was collected using 543-nm excitation and >560-nm emission
ﬁlters. Hoechst ﬂuorescence was imaged with 720-nm excitation light
from a two-photon Mira 900 laser and a >420-nm emission ﬁlter using
a Zeiss 510 NLO laser scanning confocal microscope.
2.5. Transient transfection of Nop30-GFP
MIA PaCa-2, HCT 116, and HeLa cells were plated on glass cover-
slips for 24 h. Subsequently, cells were transiently transfected with 1 lg
of plasmid containing nucleolus protein of 30 kDa (Nop30) tagged
with GFP using LipofectAMINE 2000 (Invitrogen). After 24 h incuba-
tion, cells were ﬁxed with 1% paraformaldehyde overnight at 4 C.Fig. 1. ARC is expressed in human cancer cells. Whole cell extracts from hu
MDA-MB-231 (lane 4), A549 (lane 5), HeLa (lane 6), Du145 (lane 7), SH-SY
heart (lane 12), rat brain (lane 13) and rat liver (lane 14), McA-RH7777 (lane
19) cells were separated by electrophoresis, blotted to PVDF membranes, an2.6. Statistical analysis
Data are presented as means ± S.E.M. from three independent
experiments. Diﬀerences were assessed by two-tailed Students t test
with Instat Software (GraphPAD, San Diego, CA). A P value < 0.05
was considered to be statistically signiﬁcant.3. Results and discussion
ARC is highly expressed in heart, skeletal muscle and brain
but is deﬁcient in liver, lung, kidney, pancreas, placenta, and
various lymphoid-hematopoietic tissues [2,5]. In order to
examine whether ARC is expressed in human cancer cells,
we assessed protein expression of ARC in a series of human
cancer cell lines. Equal amounts of protein from whole cell ly-
sates prepared from 10 human cancer cell lines were loaded
onto SDS–PAGE gels and analyzed by Western blot with an
anti-ARC antibody (Fig. 1). Among these human cancer cell
lines, ARC protein was detected in nine cell lines: MIA
PaCa-2 pancreatic carcinoma (Fig. 1, lane 2); HCT 116 colo-
rectal carcinoma (lane 3); MDA 231 breast carcinoma (lane
4); A549 lung carcinoma (lane 5); HeLa cervical carcinoma
(lane 6); DU 145 prostate carcinoma (lane 7); U-87 glioblas-
toma (lane 9); BJAB and DG-75 lymphoma (lane 10 and
11). ARC was not detected in SH-SY5Y neuroblastoma (lane
8). Tubulin was used as a loading control and was variable be-
tween diﬀerent cell lines and tissue types. This likely reﬂects
diﬀerent levels of tubulin protein expression in the diﬀerent cell
types. For example, tubulin-rich brain tissue showed the dens-
est tubulin band on the gels.
In adherent cancer cell lines (Fig. 1, lanes 2–7, 9) and human
skeletal muscle (lane 1), ARC migrated at approximately
34 kDa. However, in suspended BJAB and DG-75 human lym-
phoma cells ARC migrated at approximately 38 kDa (Fig. 1,
lanes 10 and 11). The 4-kDa diﬀerence in protein migration
suggests that ARC in lymphoma cell lines may have diﬀerent
post-translational modiﬁcations from ARC in other human
cancer cell lines.man skeletal muscle (lane 1), MIA PaCa-2 (lane 2), HCT 116 (lane 3),
5Y (lane 8), U87 (lane 9), BJAB (lane 10), DG-75 (lane 11), adult rat
15), ASD30 (lane 16), N1-S1 (lane 17), H9c2 (lane 18), and PC6 (lane
d probed for ARC by Western blotting.
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tissues and cancer cell lines from rats. The molecular weight
of ARC proteins from rat heart and rat brain was approxi-
mately 30 kDa (Fig. 1, lanes 12 and 13), in agreement with
an earlier report [8]. ARC was not detected in rat liver (lane
14), which also conﬁrmed the earlier report [3]. ARC expres-
sion in rat hepatoma cells was cell-line dependent. ARC was
not detected in ASD30 cells (lane 16) but was highly ex-
pressed in McA RH7777 and N1-S1 cells (lanes 15 and
17). The observation that ARC is expressed in various cancer
cell lines including hepatoma lines but not in normal liver
suggests that ARC may play a role in carcinogenesis. ARCFig. 2. ARC localizes to the nuclei of human cancer cells. (A) HCT 116 (a)
hippocampal neurons (e) and human skeletal muscle (f) were immunostained
IgG (H + L). Blue ﬂuorescence of Hoechst and green ﬂuorescence of Alexa
images. Scale bars are 20 lm. (B) Nuclear and cytoplasmic extracts of H9c2
described in Section 2 and subjected to Western blot analysis using anti-ARC
of three independent experiments. (C) Band intensities of ARC proteins f
expressed as means ± S.E.M. from three independent experiments. \P < 0.0
Students t test.was also highly expressed in rat pheochromocytoma PC-6
cells (lane 19).
ARC from H9c2 rat embryonic heart cells migrated at a
molecular weight approximately 1 kDa lower than from other
rat non-cancer and cancer cells (Fig. 1, lane 18). This observa-
tion is in agreement with a previous report showing a 12-amino
acid deletion in the C-terminus of ARC in H9c2 cells [8]. The
signiﬁcance of this deletion remains unknown.
Human and rat ARC contains 208 and 221 amino acids,
respectively [2]. Therefore, the molecular weight of human
ARC should be smaller than that of rat ARC. However, in
this study human ARC migrated at a molecular weight, MDA-MB-231 (b), MIA PaCa-2 (c), H9c2 (d), primary cultured rat
with anti-ARC antibody, followed by Alexa Fluor 488 goat anti-rabbit
488 were imaged by confocal microscopy. Shown are representative
, MIA PaCa-2, HCT 116, and MDA-MB-231 cells were prepared as
, NQO-1, and YY-1 antibodies, respectively. The blot is representative
rom cytoplasmic and nuclear extracts were quantiﬁed. Results were
5; \\P < 0.01 compared to cytosolic extracts as assessed by two-tailed
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gests post-translational modiﬁcations especially of human
ARC. Collectively, the results in Fig. 1 demonstrate that
ARC is highly expressed in various human and rat cancer cells
and has the same molecular weight as ARC in normal tissue.
The exception is suspended lymphoma cells where the appar-
ent molecular weight of ARC is approximately 4 kDa greater.
The results in Fig. 1 demonstrated ARC protein expression
in various human and rat cancer cell lines. We then investi-
gated whether the subcellular localization of ARC diﬀered be-
tween non-cancer and cancer cells by immunocytochemistry.
In non-transformed rat H9c2 embryonic heart cells and pri-
mary cultured hippocampal neurons, ARC localized to the
cytoplasm. Dark unlabeled voids in the ARC images corre-
sponded to the Hoechst-stained nuclei (Fig. 2A, panels d and
e). In human skeletal muscle ﬁbers, ARC was also diﬀusely
localized to the cytoplasm (Fig. 2A, panel f). By contrast, in
three human cancer cell lines, HCT 116, MB-MDA-231, and
MIA PaCa-2, ARC was predominantly localized to nuclei
(Fig. 2A, panels a–c). In these cells, the ﬂuorescence pattern
of ARC was punctate, suggesting that it was bound to subnu-
clear structures. ARC was also localized to nuclei in the
following cell lines: human A549 small-cell lung adenocarci-
noma, DU 145 prostate carcinoma, U-87 glioblastoma, HeLa
cervical carcinoma, HCT 116 Bax+/ and Bax/ colorectal
carcinoma (data not shown).
To further conﬁrm the nuclear localization of ARC in cancer
cells, we prepared nuclear and cytoplasmic extracts and ana-
lyzed ARC protein levels with Western blotting. In H9c2 cells,
ARC protein was predominantly detected in the cytoplasmic
extracts, while in human MIA PaCa-2 pancreatic carcinoma
cells ARC was exclusively detected in the nuclear extracts
(Fig. 2B and C). In human HCT 116 colorectal carcinoma cellsFig. 3. Nuclear ARC in the human cancer cells does not co-localize with N
Nop30 plasmid, followed by immunocytochemistry using anti-ARC antib
representative confocal images. Scale bar is 20 lm.and human MDA-MB-231 mammary adenocarcinoma cells,
the majority of ARC was detected in the nuclear extracts
although a small portion of ARC was also detected in the cyto-
plasmic fractions (Fig. 2B and C). To conﬁrm the purity of the
nuclear and cytoplasmic extracts, YinYang 1 (YY-1) and
NAD(P)H:quinone oxidoreductase 1 (NQO-1) were used as
nuclear and cytoplasmic markers, respectively. YY-1 was
exclusively detected in nuclear extracts whereas NQO-1 was
detected in cytoplasmic extracts. MDA-MB-231 cells, how-
ever, did not express NQO-1, as reported previously [10]
(Fig. 2B). Taken together, these results show nuclear ARC
localization in the large majority of cancer cells compared to
non-cancer cells. Previously, nuclear localization of ARC
was also described for PC12 rat pheochromocytoma cells
[11]. Thus, nuclear ARC seems to be a frequent feature of
neoplastically transformed cells.
Human ARC has an alternative-spliced isoform, Nop30,
which is present in the nucleoplasm and enriched in nucleoli.
ARC and Nop30 share the same N-terminus [12]. To exclude
the possibility that our ARC antibody also recognizes
Nop30, we expressed an exogenous Nop30-GFP fusion protein
in MIA PaCa-2 cells and stained endogenous ARC with anti-
ARC antibody (Fig. 3). Although both ARC and Nop30-GFP
were detected in nuclei, ARC immunostaining and Nop30-
GFP ﬂuorescence did not co-localize (Fig. 3, panel B, two bot-
tom cells). Nop30 localized to the nucleoli, whereas ARC was
excluded from the nucleoli but enriched in the nucleoplasm
(Fig. 3). These results conﬁrm that the ARC antibody does
not detect Nop30.
Analysis of the deduced amino acid sequence of the N-termi-
nus of ARC revealed a putative bipartite nuclear targeting sig-
nal which consists of two clusters of basic amino acids [13]. In
normal myogenic tissues and hippocampal neurons ARC isop30. MIA PaCa-2 cells were transiently transfected with GFP tagged
ody and Alexa Fluor 543 goat anti-rabbit IgG (H + L). Shown are
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that this putative nuclear localization signal (NLS) is not func-
tional in non-cancer cells. However, in cancer cells ARC was
localized to nuclei (Fig. 2A, panels a–c), suggesting that NLS
is modiﬁed during carcinogenesis such that it now acts as a
functional NLS by importing ARC into the nucleus. However,
further studies need to be performed to conﬁrm this possibility.
At the post-translational level, ARC can be phosphorylated
by casein kinase II (CK2) at threonine 149, and this phosphor-
ylation targets ARC to mitochondria [14]. The other ﬁve po-
tential CK2 phosphorylation sites are at serine 67, 85, 113
and threonine 41, 160 [13]. CK2 has been implicated in phos-
phorylation of certain nuclear proteins including c-myc, Max,
c-myb, c-jun, and SV40 large T-antigen [15]. It remains to be
determined whether those ﬁve potential phosphorylation sites
are modiﬁed in vivo, and whether phosphorylation or dephos-
phorylation at these sites may regulate the nuclear localization
of ARC in human cancer cells.
ARC is deﬁcient in non-myogenic tissue including liver,
lung, kidney, pancreas, placenta, and lymphoid-hematopoi-
etic tissues [2,5]. However, when tumors arise from those tis-
sues, ARC is highly expressed and localized to nuclei (Figs.
1 and 2). Therefore, ARC is a novel tumor marker and
could be potentially used for diagnosis of cancer. Further
studies are needed to understand how ARC is modiﬁed dur-
ing neoplastic transformation, the mechanism of ARC local-
ization to nuclei of cancer cells, and the biological
signiﬁcance of ARC nuclear localization to apoptosis resis-
tance in cancer cells.
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